G
Günther R. Adolf
Researcher at Boehringer Ingelheim
Publications - 65
Citations - 3400
Günther R. Adolf is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 22, co-authored 65 publications receiving 3192 citations. Previous affiliations of Günther R. Adolf include Research Institute of Molecular Pathology.
Papers
More filters
Journal ArticleDOI
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Martin Steegmaier,Matthias Hoffmann,Anke Baum,Péter Lénárt,Mark Petronczki,Martin Krššák,Ulrich Gürtler,Pilar Garin-Chesa,Simone Lieb,Jens Quant,Matthias Grauert,Günther R. Adolf,Norbert Kraut,Jan-Michael Peters,Wolfgang J. Rettig +14 more
TL;DR: A potent small-molecule inhibitor of mammalian Plk1, BI 2536, is reported, which inhibits PlK1 enzyme activity at low nanomolar concentrations and causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.
Journal Article
Expression of CD44 Variant Proteins in Human Colorectal Cancer Is Related to Tumor Progression
V. J. M. Wielenga,K H Heider,G. J. A. Offerhaus,Günther R. Adolf,F. M. Van Den Berg,Helmut Ponta,Peter Herrlich,S. T. Pals +7 more
TL;DR: The observation that CD44 variants containing a protein domain of CD44 that confers full metastatic potential to rat carcinoma and sarcoma cell lines is increasingly expressed during colorectal tumor progression indicates that this domain may have an important role in tumor progression and metastasis in humans.
Journal ArticleDOI
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph,Martin Steegmaier,Matthias Hoffmann,Matthias Grauert,Anke Baum,Jens Quant,Christian Haslinger,Pilar Garin-Chesa,Günther R. Adolf +8 more
TL;DR: Findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clinical studies have been initiated and a novel clinical candidate is described.
Journal ArticleDOI
Identification of tumor antigens in renal cell carcinoma by serological proteome analysis.
Christoph St. Klade,Tilman Voss,Edeltraud Dr. Krystek,Horst Ahorn,Kurt Zatloukal,Karl Pummer,Günther R. Adolf +6 more
TL;DR: Serological proteome analysis may be a new tool for the identification of tumor‐associated antigens in patients with nontumorous kidney and renal cell carcinoma by two‐dimensional gel electrophoresis and silver staining.
Journal ArticleDOI
Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.
Adolf Himmler,Ingrid Maurer-Fogy,Martin Krönke,Peter Scheurich,Klaus Pfizenmaier,Mikael Lantz,Inge Olsson,Rudolf Hauptmann,Christian Stratowa,Günther R. Adolf +9 more
TL;DR: Partial amino acid sequencing of human TNF-BP is reported as well as the isolation, sequence, and expression of cDNA clones encoding a human and rat TNF receptor.